Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: Comparison with nonrandomized historical control individuals

Source: MDLinx, April 2020

Researchers undertook a retrospective, nonrandomized, interventional cohort analysis to assess visual outcomes after the administration of prophylactic intravitreal bevacizumab in patients with plaque-irradiated uveal melanoma. This inquiry was performed at Wills Eye Hospital, Philadelphia, Pennsylvania. Between 2008 and 2018, prophylactic bevacizumab was delivered to 1,131 eyes with irradiated uveal melanoma (bevacizumab group) and comparison with 117 eyes with irradiated uveal melanoma was performed between 2007 and 2009 (no bevacizumab [historical control] group). They administered prophylactic intravitreal bevacizumab at the time of plaque removal as well as 6 subsequent injections were delivered at 4-month intervals over 2 years. Less optical coherence tomography proof of cystoid macular edema at 24 months and 36 months, less clinical proof of radiation maculopathy at 24 months, 36 months, and 48 months, and less clinical evidence of radiation papillopathy at 18 months was found in the bevacizumab group, in survival analysis. In a retrospective cohort of patients with uveal melanoma who received plaque radiotherapy and prophylactic intravitreal bevacizumab, better visual outcomes were observed relative to nonrandomized historical control people through 4 years.